Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal ® ) in glioma patients in China.

MLA

Hu, Chaoying, et al. “Bioequivalence Study of 20-Mg and 100-Mg Temozolomide Capsules (TOZ309 and Temodal ® ) in Glioma Patients in China.” Cancer Chemotherapy and Pharmacology, vol. 86, no. 6, Dec. 2020, pp. 793–801. EBSCOhost, https://doi.org/10.1007/s00280-020-04175-0.

APA

Hu, C., Lin, Q., Liu, C., Liu, J., Chen, X., Li, X., Zhao, G., & Zhang, L. (2020). Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal ® ) in glioma patients in China. Cancer Chemotherapy and Pharmacology, 86(6), 793–801. https://doi.org/10.1007/s00280-020-04175-0

Chicago

Hu, Chaoying, Qingtang Lin, Chuan Liu, Jacqueline Liu, Xiaobao Chen, Xinxia Li, Guoguang Zhao, and Lan Zhang. 2020. “Bioequivalence Study of 20-Mg and 100-Mg Temozolomide Capsules (TOZ309 and Temodal ® ) in Glioma Patients in China.” Cancer Chemotherapy and Pharmacology 86 (6): 793–801. doi:10.1007/s00280-020-04175-0.